trastuzumab
astrazeneca,daiichi sankyo
['tnbc', 'trastuzumab', 'mbc']
new standard of care in her2 low mbc with trastuzumab-deruxtecan not only in rh+ sub population but also in tnbc. amazing results #asco22 #breatcancer #trastuzumabderuxtexan 